Rajni Kannan Discusses Immune Related Adverse Events

Elizabeth Aronson, MSN, FNP-BCN, OCN, discusses how the recent approvals of elranatamab and talquetamab are changing the treatment landscape for patients with multiple myeloma.

Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.

Jennifer Cargile, MEd, CCC-SLP, shares some signs and symptoms of cancer-related cognitive impairment that the oncology nurse should be looking out for.

In this episode of "The Vitals," Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP, shares her experience helping a patient reduce their opioid use through acupuncture treatments.

There is room to improve drug adherence, patient education, and adverse event (AE) management for interstitial lung disease and cardiac AEs, according to Patricia Jakel, RN, MN, AOCN.

Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.